Stock Chart
CELC
Type: SELL wallstreet
Strike: $115
Premium: $29.78
Expiry: Jan 15, 2027
Target: $121
Score: -80
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About CELC - Celcuity Inc. Common Stock
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Key Statistics
More CELC Analysis
This CELC stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track CELC's price movements with trendlines, gamma walls, and key support/resistance levels.